Pharma Friend? IXICO Seeks To Boost MS Drug Sales With Brain Health Tech
This article was originally published in Clinica
IXICO has struck a partnership with a major pharma player to help improve clinical outcomes of the latter’s blockbuster drug for multiple sclerosis – which will hopefully lead to increased sales – by adding the use of IXICO’s Assessa digital brain health monitoring technology to better manage a serious and potentially fatal side effect of the therapy.
You may also be interested in...
Brain-health company IXICO is ready to seize pharma's digital health opportunities by expanding into the companion digital health product sector. Last year the company partnered with Biogen to pilot its digital platform Assessa with the drug TYSABRI.
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.